• Username (E-mail)
  • Password
Dow 20,810 0.2%  EStoxx50 3,286 -1.4%  Nikkei 19,284 -0.5%  EUR 1.0610 0.3% 
Nasdaq 5,836 -0.4%  FTSE100 7,213 -0.8%  Yen 112.2030 -0.5%  Oil 56.1 -0.7% 
S&P500 2,364 0.0%  DAX 11,743 -1.7%  GBP 1.2556 0.0%  Gold 1,258 0.7% 

Biogen share [Symbol: BIIB / ISIN: US09062X1037]

Realtimequote Biogen Inc in USD

Exchange Market
284.64
Last
0
Volume
Time 03:59 PM
02/23/2017 03:59:59 PM UTC-0500
activate push

Stock Price Biogen Inc in USD

Activate push
284.75 USD -2.88 USD -1.00 %
Trade Time 8:10 PM Trade Date 2/23/2017
Daily High 0.00 Open 0.00
Daily Low 0.00 Prev. Close 287.63
52-week High 306.75 Volume (Qty.) 0
52-week Low 205.30 Market Cap (USD) 62.13 B
52-week Perf.
Exchange

Analyst Opinions for Biogen Inc

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
12/17/12
Biogen Goldman Sachs Group Inc.
12/11/12
Biogen Credit Suisse Group
10/18/12
Biogen Jefferies & Company Inc.
10/12/12
Biogen UBS AG
09/28/12
Biogen Jefferies & Company Inc.

Moody's Rating for Biogen Inc

Investment Grade (High Grade)
Investment Grade (Medium Grade)
Speculative Grade
Rating Baa1
Rating Update AFF
Date of Rating 9/10/2015
Rating Office USA

Profile Biogen Inc

Company Profile
Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded by Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
pagehit

Add or Edit Instrument

Biogen Chart - 1 Year - NAS
  • Intraday
  • 1w
  • 3 Mo.
  • 1y
  • 3y
  • 5y
  • Max
  • Exchange: NAS
  • Chart Options

Estimates for Biogen

2016 2017e 2018e
Dividend - - -
Dividend Yield in % - - -
P/E Ratio 13.05 12.47 11.61
EPS 20.22 20.98 22.54

Biogen Key Figures

Market Cap (USD) 62.13 B
Free Float in % 99.84
Number of Shares (Mio.) 215.95
Cash Flow per Share 15.43
Book Value per Share 53.46
60-Days Volatility 25.46
P/B Ratio 4.94

Base Data Biogen

Symbol BIIB
ISIN US09062X1037
Indices NASDAQ Comp., S&P 500, NASDAQ 100, S&P 100, BX Swiss - USA

About the Company Biogen

Country USA

Biogen Historical Prices

02/21/2017
02/21/2017 06:00:00 PM UTC-0500
287.63 399,658
02/20/2017
02/20/2017 06:00:00 PM UTC-0500
286.90 414,878
02/16/2017
02/16/2017 06:00:00 PM UTC-0500
288.94 773,463
02/15/2017
02/15/2017 06:00:00 PM UTC-0500
290.13 632,842
02/14/2017
02/14/2017 06:00:00 PM UTC-0500
292.64 924,220

Biogen Peer Group

Agennix 0.05
-40.6%
Amgen 174.01
0.8%
BB BIOTECH 56.35
-2.3%
Bayer 104.25
-0.7%
Biogen 284.75
-1.0%
Biotest 19.00
-2.8%
EVOTEC 7.13
-3.0%
Gilead Sciences 69.37
0.8%
KWS SAAT 286.80
-0.1%
MorphoSys 52.17
-1.5%
QIAGEN 26.35
-1.3%
Sartorius vz 70.17
-0.3%
UCB 66.06
-1.0%

Similar shares with higher 1-year perf.